Health Economics›Classical Hodgkin lymphoma pediatric›Upfront therapy, Intermediate Risk

Upfront therapy, Intermediate Risk

Classical Hodgkin lymphoma pediatric · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
ABVE-PC Partial	—	R 7 248	21d	—	—	~5	~R 19 061 indirect	—
DECA Variant #01	—	R 1 863	21d	—	—	~2	~R 3 727 indirect	—

2 of 2 regimens shown